A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small C
A phase 3 trial of Alectinib, Entrectinib, Durvalumab in non-small-cell lung cancer and small-cell lung cancer, run by Hoffmann-La Roche, active and no longer recruiting.
Overview
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) is a phase 3 interventional study registered as NCT05170204 by Hoffmann-La Roche, with 68 participants enrolled, started 2022-11-01 and due to reach its primary completion in 2030-06-16. Interventions recorded: Alectinib, Entrectinib, Durvalumab. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialBasket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangeme
Shares Entrectinib, Roche / Genentech, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Shares Alectinib, Entrectinib, Roche / Genentech, Small-cell lung cancer.
- TrialA Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
Shares Alectinib, Roche / Genentech, Small-cell lung cancer, Non-small-cell lung cancer.
- CompanyChugai Pharmaceutical
Shares Alectinib, Roche / Genentech, Non-small-cell lung cancer.
- TrialPharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms
Shares Alectinib, Non-small-cell lung cancer.
- TrialStudy to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D,
Shares Durvalumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
Shares Roche / Genentech, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialNeladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Shares Alectinib, Small-cell lung cancer, Non-small-cell lung cancer.